Novo Nordisk Faces Setback in Kidney Disease Drug Trial

Novo Nordisk recently saw a major drug trial fail. Their medicine, ziltivekimab, aimed to treat chronic kidney disease. This drug did not reach its main target in a key study.

Experts believed ziltivekimab could earn huge sales. It was also meant to help Novo Nordisk offer more types of medicines. The trial results are a blow to these plans.

Despite this, Novo Nordisk has hope. They are running two more trials, called Artemis and Hermes. These studies could still save the drug program. The company will continue to test the medicine's potential.

This news shows the risks in developing new drugs. Even promising medicines can face hurdles. Investors and patients will watch closely for updates from the Artemis and Hermes trials.

Source: FierceBiotech